Results 211 to 220 of about 435,266 (312)

Glutamatergic Targets for Enhancing Extinction Learning in Drug Addiction

, 2010
Richard M. Cleva, Justin T. Gass, John J. Widholm, M. Foster Olive   +3 more
openalex   +2 more sources

High effectiveness of self-help programs after drug addiction therapy [PDF]

, 2006
John‐Kåre Vederhus, Øistein Kristensen   +1 more
openalex   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Molecular and Epigenetic Aspects of Opioid Receptors in Drug Addiction and Pain Management in Sport. [PDF]

Int J Mol Sci, 2023
Mazzeo F, Meccariello R, Guatteo E.
europepmc   +1 more source

Utilizing Social Media for Identifying Drug Addiction and Recovery Intervention

, 2020
Shalmoli Ghosh, Janardan Misra, Saptarshi Ghosh, Sanjay Podder   +3 more
openalex   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

To Incarcerate or Not to Incarcerate: Is That the Right Question for Drug Addiction? [PDF]

Can J Psychiatry, 2022
Johnstone S, Sorkhou M, Castle DJ, George TP.   +3 more
europepmc   +1 more source

LOCUS PRAEVENTIONI MELIOR QUAM REMENDIUM. THE ICELANDIC PREVENTION MODEL IN THE FIGHT AGAINST YOUTH ADDICTIONS: ALCOHOL, TOBACCO, AND DRUGS

, 2023
Francesco MASTROCOLA, Elena CERNOIU
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

An economon model of drug addiction. [PDF]

Psychopharmacology (Berl)
Negus SS.
europepmc   +1 more source